Media Relations Contact: Senesco Technologies, Inc. FD FD Joel Brooks Brian Ritchie Irma Gomez-Dib Chief Financial Officer brian.ritchie@fd.com irma.gomez-dib@fd.com jbrooks@s

TECHNOLOGIES ENTERS INTO AGREEMENTS FOR ADDITIONAL $700,000 IN

NEW BRUNSWICK, N.J. (July

Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT)

today announced that, on July 29, 2009, the Company entered into definitive

purchase agreements with certain members of Senesco's Board of Directors and

certain accredited investors, including Cato Holding Company, which is the

venture capital affiliate of Cato Research Ltd., a global contract research and

development organization currently assisting Senesco with its SNS-101

development program with the emphasis on initiating a Phase I clinical trial for

to the respective purchase agreements, Senesco will issue and sell (i) up to

783,332 shares of its common stock (the "Shares") at a price of $0.90 per share,

(ii) warrants to purchase an aggregate of up to 705,000 shares of common stock,

which warrants are exercisable immediately at an exercise price of $0.01 per

share (the "Series A Warrants") and (iii) warrants to purchase an aggregate of

up to 714,794 shares of common stock, which warrants are exercisable 6 months

from the date of issuance at an exercise price of $0.60 per share (the "Series B

Warrants"). In connection with the private placement, the Company

anticipates that it will receive aggregate proceeds, excluding costs and

expenses, in the amount of $530,000. In addition, Cato Holding

Company has agreed to cancel $175,000 of the Company's indebtedness to Cato

Research, Ltd., bringing the proceeds of the offering, excluding costs and

expenses, to approximately $705,000.

closing of the foregoing transactions is contingent upon Senesco receiving

stockholder approval for certain aspects of the transactions as well as other

customary closing conditions. There are no registration rights

associated with the securities to be issued and sold in the private placement

and no placement agent was used in connection with the private

primarily intends to utilize the net proceeds of these transactions to further

advance its multiple myeloma research and development program with the goal of

initiating a Phase I clinical trial.

excited by the potential of SNS-101 as a novel treatment alternative for

multiple myeloma," said Allen Cato, MD, PhD, CEO of Cato Research. "Our recent

investment reflects our confidence in the Company's regulatory and development

plans. We look forward to significant progress in the months

gratified by the confidence expressed in us by our CRO, the Board members and

accredited investors involved in this transaction," commented Joel Brooks, Chief

Financial Officer. "This funding, along with the $1 million in

financing secured several weeks ago, enables us to continue moving forward

efficiently with our goal of filing an Investigational New Drug Application and

initiating a Phase I clinical trial for SNS-01."

press release shall not constitute an offer to sell or the solicitation of an

offer to buy, nor shall there be any sale of these securities in any state in

which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such state. The shares

of common stock have been sold pursuant to an exemption from state and federal

connection with the private placement, the Company will prepare a proxy

statement for the Company's stockholders to be filed with the Securities and

Exchange Commission (the "SEC"). The proxy statement will contain information

about the Company, the private placement and related matters. STOCKHOLDERS

ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT IS AVAILABLE, AS IT WILL

CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE

MAKING A DECISION ABOUT APPROVING AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF

INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES.

addition to receiving the proxy statement from the Company by mail, shareholders

will be able to obtain the proxy statement, as well as other filings containing

information about the Company, without charge, from the SEC's website (http://www.sec.gov )

or, without charge, from the Company's website at www.senesco.com or

by directing such request to Senesco Technologies, Inc. 303 George

St., Suite 420, New Brunswick, New Jersey 08901 Attention: Joel

Company and its directors and executive officers and other members of management

and employees may be deemed to be participants in the solicitation of proxies.

Information concerning the Company and its directors and executive

officers is set forth in the Company's proxy statement and Annual Report on Form

10-K previously filed with the SEC.

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay

cell death in mammals (apoptosis) to determine if the technology is applicable

in human medicine. Accelerating apoptosis may have applications to development

of cancer treatments. Delaying apoptosis may have applications to certain

diseases inflammatory and ischemic diseases. Senesco takes its name from the

scientific term for the aging of plant cells: senescence. Delaying cell

breakdown in plants extends freshness after harvesting, while increasing crop

yields, plant size and resistance to environmental stress. The Company

believes that its technology can be used to develop superior strains of crops

without any modification other than delaying natural plant senescence.

Senesco has partnered with leading-edge companies engaged in agricultural

biotechnology and earns research and development fees for applying its

gene-regulating platform technology to enhance its partners'

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results could differ materially from such statements expressed or implied

herein as a result of a variety of factors, including, but not limited to: the

Company's ability to consummate this financing as well as additional financings;

the development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, as well as other

factors expressed from time to time in the Company's periodic filings with the

SEC. As a result, this press release should be read in conjunction with the

Company's periodic filings with the SEC. The forward-looking statements

contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.